单位：[1]Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China[2]Department of Pulmonary and Critical Care Medicine, National Centre for Respiratory Medicine, Centre of Respiratory Medicine, National Clinical Research Centre for Respiratory Diseases,China-Japan Friendship Hospital, Beijing 100029, China[3]Institute of Clinical Medical Sciences,China-Japan Friendship Hospital, Beijing 100029, China[4]Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China[5]Tsinghua University-Peking University Joint Centre for Life Sciences, Beijing, China
出处：
ISSN：
基金：
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [CIFMS 2018-I2M-1-003, 2020-I2M-CoV19-005]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82041011/H0104]; National Key Research and Development Programme of China [2018YFC1200102]; Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis [2020ZX09201001]; China Evergrande Group; Jack Ma Foundation; New Sunshine Charity Foundation; Sino Biopharmaceutical; Ping An Insurance Group
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China[2]Department of Pulmonary and Critical Care Medicine, National Centre for Respiratory Medicine, Centre of Respiratory Medicine, National Clinical Research Centre for Respiratory Diseases,China-Japan Friendship Hospital, Beijing 100029, China
通讯作者：
通讯机构：[2]Department of Pulmonary and Critical Care Medicine, National Centre for Respiratory Medicine, Centre of Respiratory Medicine, National Clinical Research Centre for Respiratory Diseases,China-Japan Friendship Hospital, Beijing 100029, China[3]Institute of Clinical Medical Sciences,China-Japan Friendship Hospital, Beijing 100029, China[4]Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China[5]Tsinghua University-Peking University Joint Centre for Life Sciences, Beijing, China
推荐引用方式(GB/T 7714)：
Lixue Huang,Xiaoying Gu,Bin Cao.Long-term effects on survivors with COVID-19 reply[J].LANCET.2021,398(10314):1872-+.
APA：
Lixue Huang,Xiaoying Gu&Bin Cao.(2021).Long-term effects on survivors with COVID-19 reply.LANCET,398,(10314)
MLA：
Lixue Huang,et al."Long-term effects on survivors with COVID-19 reply".LANCET 398..10314(2021):1872-+
医学